Sample benchmark sheets · Oncology
Check our work before you sign up
5 benchmarks you can read without an account. Each shows the lowest approved precedent, the trials behind it, a link to each paper and the limits of the numbers. This is precedent, not an FDA requirement.
- First-line metastatic NSCLC: PFS in Phase 3 trials+4.3 monthsLowest approved precedent, from 5 trials
- Previously treated, biomarker-selected NSCLC: ORR in single-arm trials37.1%Lowest approved precedent, from 4 trials
- Heavily pretreated multiple myeloma: ORR in single-arm trials25.3%Lowest approved precedent, from 4 trials
- Relapsed or refractory DLBCL: complete response in single-arm trials24.1%Lowest approved precedent, from 4 trials
- Refractory metastatic colorectal cancer: OS in Phase 3 trials+1.4 monthsLowest approved precedent, from 3 trials
Look up an indication you know well
This is a sample. The app has the rest of our benchmark library, which is mostly oncology, and tracks changes to the ClinicalTrials.gov records of the programs you watch. It is free during early access, with no card needed.